CD28-pathway blockade with CTLA4Ig leads to prolongation of small bowel transplant survival in rats.
Pescovitz
M D
MD
Department of Surgery, Indiana University, Indianapolis 46202.
Yang
R
R
Liu
Q
Q
Collins
M H
MH
Grosfeld
J L
JL
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D018106:CD28 Antigens / Q000502:physiology*; D060908:CTLA-4 Antigen; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D006801:Humans; D018796:Immunoconjugates; D007141:Immunoglobulin Fc Fragments / Q000627:therapeutic use*; D007421:Intestine, Small / Q000637:transplantation*; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; D000069594:Abatacept